Large-volume IM injections: A review of best practices
Intramuscular injections offer improved treatment adherence, ease in monitoring of adverse effects, and multiple administration sites.
Fulvestrant
Higher fulvestrant doses prolonged survival in patients with advanced breast cancer
Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to updated data from the CONFIRM trial.
Alternate dosing regimens for estrogen receptor antagonist
Studies show that alternate dosages of fulvestrant may be efficacious, and adverse effects are similar in all regimens.
FDA-Approved Drugs Treat and Prevent Cervical Cancer in Mice
Two FDA-approved drugs may be as effective in treating cervical cancer in human cells as they are in mice, say researchers at the University of Wisconsin-Madison School of Medicine and Public Health.
